ABSTRACT
BACKGROUND: OptimalTTF-2 is a randomized, comparative, multi-center, investigator-initiated, interventional study aiming to test skull remodeling surgery in combination with Tumor Treating Fields therapy (TTFields) and best physicians choice medical oncological therapy for first recurrence in glioblastoma patients. OptimalTTF-2 is a phase 2 trial initiated in November 2020. Skull remodeling surgery consists of five burrholes, each 15 mm in diameter, directly over the tumor resection cavity. Preclinical research indicates that this procedure enhances the effect of Tumor Treating Fields considerably. We recently concluded a phase 1 safety/feasibility trial that indicated improved overall survival and no additional toxicity. This phase 2 trial aims to validate the efficacy of the proposed intervention. METHODS: The trial is designed as a comparative, 1:1 randomized, minimax two-stage phase 2 with an expected 70 patients to a maximum sample size of 84 patients. After 12-months follow-up of the first 52 patients, an interim futility analysis will be performed. The two trial arms will consist of either a) TTFields therapy combined with best physicians choice oncological treatment (control arm) or b) skull remodeling surgery, TTFields therapy and best practice oncology (interventional arm). Major eligibility criteria include age ≥ 18 years, 1st recurrence of supratentorial glioblastoma, Karnofsky performance score ≥ 70, focal tumor, and lack of significant co-morbidity. Study design aims to detect a 20% increase in overall survival after 12 months (OS12), assuming OS12 = 40% in the control group and OS12 = 60% in the intervention group. Secondary endpoints include hazard rate ratio of overall survival and progression-free survival, objective tumor response rate, quality of life, KPS, steroid dose, and toxicity. Toxicity, objective tumor response rate, and QoL will be assessed every 3rd month. Endpoint data will be collected at the end of the trial, including the occurrence of suspected unexpected serious adverse reactions (SUSARs), unacceptable serious adverse events (SAEs), withdrawal of consent, or loss-to-follow-up. DISCUSSION: New treatment modalities are highly needed for first recurrence glioblastoma. Our proposed treatment modality of skull remodeling surgery, Tumor Treating Fields, and best practice medical oncological therapy may increase overall survival significantly. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT0422399 , registered 13. January 2020.
Subject(s)
Brain Neoplasms/surgery , Glioblastoma/surgery , Neoplasm Recurrence, Local/surgery , Osteotomy/methods , Skull/surgery , Adult , Follow-Up Studies , Glioblastoma/mortality , Humans , Karnofsky Performance Status , Neoplasm Recurrence, Local/mortality , Progression-Free Survival , Prospective Studies , Quality of Life , Time Factors , TransducersABSTRACT
BACKGROUND AND PURPOSE: Radiographic assessment of cerebral metastasis after stereotactic radiosurgery remains a major challenge in neuro-oncology. It is often difficult to distinguish tumor progression from radiation necrosis in this setting using conventional MR imaging. The objective of this study was to compare the diagnostic sensitivity and specificity of different functional imaging modalities for detecting tumor recurrence after stereotactic radiosurgery. MATERIALS AND METHODS: We retrospectively reviewed patients treated between 2007 and 2010 and identified 14 patients with cerebral metastasis who had clinical or radiographic progression following stereotactic radiosurgery and were imaged with arterial spin-labeling, FDG-PET, and thallium SPECT before stereotactic biopsy. Diagnostic accuracy, specificity, sensitivity, positive predictive value, and negative predictive value were calculated for each imaging technique by using the pathologic diagnosis as the criterion standard. RESULTS: Six patients (42%) had tumor progression, while 8 (58%) developed radiation necrosis. FDG-PET and arterial spin-labeling were equally sensitive in detecting tumor progression (83%). However, the specificity of arterial spin-labeling was superior to that of the other modalities (100%, 75%, and 50%, respectively). A combination of modalities did not augment the sensitivity, specificity, positive predictive value, or negative predictive value of arterial spin-labeling. CONCLUSIONS: In our series, arterial spin-labeling positivity was closely associated with the pathologic diagnosis of tumor progression after stereotactic radiosurgery. Validation of this finding in a large series is warranted.
Subject(s)
Brain Neoplasms/diagnostic imaging , Neoplasm Recurrence, Local/diagnostic imaging , Radiation Injuries/diagnostic imaging , Radiosurgery/adverse effects , Adult , Aged , Brain Neoplasms/diagnosis , Brain Neoplasms/secondary , Diagnosis, Differential , Disease Progression , Female , Humans , Male , Middle Aged , Necrosis/diagnostic imaging , Positron-Emission Tomography , Retrospective Studies , Spin Labels , Tomography, Emission-Computed, Single-PhotonABSTRACT
BACKGROUND: Patients with recurrent glioblastoma have a poor outcome. Data from the phase III registration trial comparing tumour-treating alternating electric fields (TTFields) vs chemotherapy provided a unique opportunity to study dexamethasone effects on patient outcome unencumbered by the confounding immune and myeloablative side effects of chemotherapy. METHODS: Using an unsupervised binary partitioning algorithm, we segregated both cohorts of the trial based on the dexamethasone dose that yielded the greatest statistical difference in overall survival (OS). The results were validated in a separate cohort treated in a single institution with TTFields and their T lymphocytes were correlated with OS. RESULTS: Patients who used dexamethasone doses >4.1 mg per day had a significant reduction in OS when compared with those who used ⩽4.1 mg per day, 4.8 vs 11.0 months respectively (χ(2)=34.6, P<0.0001) in the TTField-treated cohort and 6.0 vs 8.9 months respectively (χ(2)=10.0, P<0.0015) in the chemotherapy-treated cohort. In a single institution validation cohort treated with TTFields, the median OS of patients who used dexamethasone >4.1 mg per day was 3.2 months compared with those who used ⩽4.1 mg per day was 8.7 months (χ(2)=11.1, P=0.0009). There was a significant correlation between OS and T-lymphocyte counts. CONCLUSIONS: Dexamethasone exerted profound effects on both TTFields and chemotherapy efficacy resulting in lower patient OS. Therefore, global immunosuppression by dexamethasone likely interferes with immune functions that are necessary for the treatment of glioblastoma.
Subject(s)
Brain Neoplasms/drug therapy , Dexamethasone/pharmacology , Glioblastoma/drug therapy , Neoplasm Recurrence, Local/drug therapy , Adult , Aged , Aged, 80 and over , Brain Neoplasms/immunology , Brain Neoplasms/mortality , Dose-Response Relationship, Drug , Electric Stimulation Therapy , Female , Glioblastoma/immunology , Glioblastoma/mortality , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/mortality , T-Lymphocytes/immunology , Treatment OutcomeABSTRACT
AIMS/HYPOTHESIS: While chronic low-grade inflammation is associated with obesity, acute inflammation reduces food intake and leads to negative energy balance. Although both types of inflammation activate nuclear factor κB (NF-κB) signalling, it remains unclear how NF-κB activation results in opposite physiological responses in the two types of inflammation. The goal of this study was to address this question, and to understand the link between inflammation and leptin signalling. METHODS: We studied the ability of NF-κB to modulate Pomc transcription, and how it impinges on signal transducer and activator of transcription 3 (STAT3)-mediated leptin signalling by using a combination of animal models, biochemical assays and molecular biology. RESULTS: We report that suppression of food intake and physical movement with acute inflammation is not dependent on STAT3 activation in pro-opiomelanocortin (POMC) neurons. Under these conditions, activated NF-κB independently leads to increased Pomc transcription. Electrophoretic mobility shift assay and chromatin immunoprecipitation (ChIP) experiments reveal that NF-κB v-rel reticuloendotheliosis viral oncogene homologue A (avian) (RELA [also known as p65]) binds to the Pomc promoter region between -138 and -88 bp, which also harbours the trans-acting transcription factor 1 (SP1) binding site. We found significant changes in the methylation pattern at this region and reduced Pomc activation under chronic inflammation induced by a high-fat diet. Furthermore, RELA is unable to bind and activate transcription when the Pomc promoter is methylated. Finally, RELA binds to STAT3 and inhibits STAT3-mediated promoter activity, suggesting that RELA, possibly together with forkhead box-containing protein 1 (FOXO1), may prevent STAT3-mediated leptin activation of the Pomc promoter. CONCLUSIONS/INTERPRETATION: Our study provides a mechanism for the involvement of RELA in the divergent regulation of energy homeostasis in acute and chronic inflammation.
Subject(s)
Eating , Gene Expression Regulation , NF-kappa B/metabolism , Pro-Opiomelanocortin/genetics , Promoter Regions, Genetic , Animals , Base Sequence , Behavior, Animal , Feeding Behavior , Inflammation , Leptin/metabolism , Male , Mice , Mice, Inbred C57BL , Molecular Sequence Data , STAT3 Transcription Factor/metabolism , Signal TransductionABSTRACT
The failure to control glioblastoma progression is a major challenge for neuro-oncologists. Emerging data indicate that genetic and epigenetic heterogeneities within tumor cells play a dominant role in the development of resistant disease. These heterogeneities develop because driver mutations enable the proliferation of certain clones of transformed cells within the tumor microenvironment while pre-existing passenger or secondary mutations emerge from the clonal selection process during treatment. In addition, epigenetic changes provide another means of modifying the existing heterogeneous genetic background of tumor cells. These cumulative changes create challenges for the detection, characterization and treatment of glioblastomas, but new opportunities allow the development of advanced diagnostic modalities and individualized therapies. Furthermore, mutations in the epidermal growth factor receptor (EGFR) alter binding capability to targeted agents like erlotinib, rendering it inactive to block EGFR signaling. Receptor class switching and tyrosine kinase decoupling from cell cycle machineries are also mechanisms that can render tumor cells resistant to EGFR blockade. Therefore, effective therapy most likely requires the combination of personalized medicine treatment offered by targeted drugs and less specific therapies that aim at other processes within the tumor microenvironment. The goal is to take advantage of the specificity offered by targeted drugs to block proliferation of tumor cells harboring driver mutations while less specific treatments can be used against cells with passenger mutations.
Subject(s)
ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Glioblastoma/genetics , Glioblastoma/therapy , Precision Medicine , Cell Cycle/genetics , Cell Proliferation/drug effects , ErbB Receptors/metabolism , Erlotinib Hydrochloride , Genetic Variation , Humans , Isocitrate Dehydrogenase/genetics , MicroRNAs/genetics , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Signal Transduction , Tumor MicroenvironmentABSTRACT
In this study, we investigated whether DHA, a nutritionally important n-3 unsaturated fatty acid, modulated the sensitivity of brain tumor cells to the anticancer drug, etoposide (VP16). Medulloblastoma (MB) cell lines, Daoy and D283, and glioblastoma (GBM) cell lines, U138 and U87, were exposed to DHA or VP16 alone or in combination. The effects on cell proliferation and the induction of apoptosis were determined by using MTS and Hoechest 33342/PI double staining. U87 and U138 cells were found to be insensitive to the addition of DHA and VP16, whereas the two MB cell lines showed high sensitivity. DHA or VP16 alone showed little effect on cell proliferation or death in either the MB or GBM cell lines, but pretreatment with DHA enhanced the responsiveness to VP16 in the MB cell lines. To understand the mechanisms of combined DHA and VP16 on MB cells, pathway specific oligo array analyses were performed to dissect possible signaling pathways involved. The addition of DHA and VP16, in comparison to VP16 added alone, resulted in marked suppression in the expression of several genes involved in DNA damage repair, cell proliferation, survival, invasion, and angiogenesis, including PRKDC, Survivin, PIK3R1, MAPK14, NFκB1, NFκBIA, BCL2, CD44, and MAT1. These results suggest (1) that the effects of DHA and VP16 in brain tumor cells are mediated in part by the down regulation of events involved in DNA repair and the PI3K/MAPK signaling pathways and (2) that brain tumors genotypically mimicked by MB cells may benefit from therapies combining DHA with VP16.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Brain Neoplasms/drug therapy , Docosahexaenoic Acids/pharmacology , Etoposide/pharmacology , Glioblastoma/drug therapy , Medulloblastoma/drug therapy , Brain Neoplasms/pathology , Carrier Proteins/genetics , Cell Cycle Proteins , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/genetics , DNA Damage/genetics , DNA Repair/genetics , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , Glioblastoma/pathology , Humans , Hyaluronan Receptors/genetics , Inhibitor of Apoptosis Proteins/genetics , Medulloblastoma/pathology , Mitogen-Activated Protein Kinase 14/genetics , NF-kappa B/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Signal Transduction/drug effects , Survivin , Transcription FactorsABSTRACT
Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is currently in phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can downregulate nuclear factor-kappa B (NF-kappaB) activation in response to tumor necrosis factor (TNF)alpha and interleukin 1. Activation of p53-dependent transcription is not compromised when R-Roscovitine is combined with TNFalpha. We characterize the molecular mechanism governing NF-kappaB repression and show that R-Roscovitine inhibits the IkappaB kinase (IKK) kinase activity, which leads to defective IkappaBalpha phosphorylation, degradation and hence nuclear function of NF-kappaB. We further show that the downregulation of the NF-kappaB pathway is also at the level of p65 modification and that the phosphorylation of p65 at Ser 536 is repressed by R-Roscovitine. Consistent with repression of canonical IKK signaling pathway, the induction of NF-kappaB target genes monocyte chemoattractant protein, intercellular adhesion molecule-1, cyclooxygenase-2 and IL-8 is also inhibited by R-Roscovitine. We further show that treatment of cells with TNFalpha and R-Roscovitine causes potentiation of cell death. Based on these results, we suggest the potential use of R-Roscovitine as a bitargeted anticancer drug that functions by simultaneously causing p53 activation and NF-kappaB suppression. This study also provides mechanistic insight into the molecular mechanism of action of R-Roscovitine, thereby possibly explaining its anti-inflammatory properties.
Subject(s)
Apoptosis/drug effects , NF-kappa B/metabolism , Purines/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Tumor Suppressor Protein p53/metabolism , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , I-kappa B Kinase/antagonists & inhibitors , I-kappa B Kinase/metabolism , I-kappa B Proteins/metabolism , Interleukin-1/metabolism , NF-KappaB Inhibitor alpha , NF-kappa B/antagonists & inhibitors , Phosphorylation/drug effects , Roscovitine , Transcription Factor RelA/antagonists & inhibitors , Transcription Factor RelA/metabolism , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Nutlins were identified as the first potent and specific small molecule Mdm2 antagonists that inhibit the p53-Mdm2 interaction. We show in this study that Nutlin-3 can downregulate TNFalpha induced activation of the NFkappaB reporter in lung cancer cells. Activation of p53 dependent transcription is not compromised when Nutlin-3 is combined with TNFalpha. Instead, this combination treatment decreases cell viability in a p53 dependent manner. We show that Nutlin-3 strikingly inhibits the protein expression of NFkappaB target genes ICAM-1 and MCP-1 while other targets like Bcl-xL and FLIP are not affected, thereby suggesting that the inhibition is promoter specific. This inhibition of ICAM-1 and MCP-1 by Nutlin-3 is again dependent on the p53 status in cells. Furthermore, we show that Nutlin-3 strongly inhibits protein expression of ICAM-1 and MCP-1 induced by IL1, another NFkappaB activating stimuli. Nutlin-3 does not inhibit Akt phosphorylation, IkappaB alpha phosphorylation, IkappaB alpha degradation, p65 modification or p65 DNA binding in the cell lines tested. This study suggests the potential of Nutlin-3 as a bitargeted anti-cancer drug by simultaneously causing p53 activation and NFkappaB suppression. It also suggests that Nutlin-3 could be evaluated for treatment of lung cancer as a single agent or in combination therapy by targeting its effect on ICAM-1 and MCP-1 which are known to be critical for cancer cell invasion, thereby downregulating tumor formation and metastasis. This study also suggests biomarkers of response for evaluation of Nutlin-3 in the clinic.
Subject(s)
Imidazoles/pharmacology , Lung Neoplasms/metabolism , Lung Neoplasms/therapy , NF-kappa B/metabolism , Piperazines/pharmacology , Tumor Suppressor Protein p53/metabolism , Animals , Cell Line, Tumor , Cell Survival/drug effects , Chemokine CCL2/genetics , DNA/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Electrophoretic Mobility Shift Assay , Genes, Reporter , Humans , I-kappa B Proteins/metabolism , Intercellular Adhesion Molecule-1/genetics , Interleukin-1/pharmacology , Mice , NF-KappaB Inhibitor alpha , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Processing, Post-Translational/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Time Factors , Transcription Factor RelA/metabolism , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
PURPOSE: his study evaluated the effectiveness of a recently developed, low-cost 'over-the-counter' style hearing aid with elderly people, who had mild to moderate mixed or sensorineural hearing losses. Two aspects were focused upon, objective change in the participants' aided hearing measures and the self-reported performance and benefit obtained from the hearing aid. METHOD: The hearing aids were trialed by 19 elderly persons over a 3-month period. Aided hearing thresholds and real-ear insertion gain measures were obtained from participants, three questionnaires (the Client-Oriented Scale of Improvement [COSI], the International Outcome Inventory for Hearing Aids [IOI-HA] and the Profile of Hearing Aid Performance--Chinese version [PHAP-C]) were completed, and an open-ended interview was conducted. RESULTS: Objective tests noted that the trial hearing aid was able to provide appropriate amplification for the elderly participants in this study. The device was rated by the majority of participants as providing benefit, with 16 of the participants (84%) using their hearing aid from at least 1 to over 8 h each day and with all participants considering the low-cost instrument 'worth the trouble' of wearing. Participant ratings of benefit with the IOI-HA were comparable with those obtained in a normative study in which subjects used more expensive conventional hearing aids. Using the COSI questionnaire, participants typically concluded that their hearing improvement with the study device was 'slightly better' to 'better' than without amplification. The PHAP-C questionnaire results indicated that, while wearing their hearing aids, participants experienced difficulties only infrequently in most everyday listening situations. Comments made during open-ended interviews were equally positive and negative, with most negative comments focused on difficulties with either acoustic feedback or background noise annoyance while wearing the hearing instrument.CONCLUSION. Affordable, over-the-counter hearing devices provide a potential opportunity for greater numbers of persons with hearing loss to access amplification and benefit from improved communicative abilities. Further investigation and further development of these instruments is warranted, to provide enhanced rehabilitation outcomes for elderly persons with hearing impairment.
Subject(s)
Hearing Aids , Aged , Aged, 80 and over , Equipment Design , Hearing Aids/economics , Hearing Loss, Sensorineural , Humans , Male , Middle Aged , Surveys and Questionnaires , Treatment OutcomeABSTRACT
Incorporation of an internal ribosome entry site (IRES) into the gene therapy vector represents a promising strategy to efficiently co-express several gene products from the same promoter. However, vector systems that utilize the encephalomyocarditis virus IRES express the downstream gene much less efficiently than the upstream gene. In this study, we compared four IRESes isolated from human genes against the EMCV IRES, using beta-galactosidase and chloramphenicol acetyl transferase genes as reporters, to evaluate their potential for providing better expression of the downstream gene. We found that an IRES from the eukaryotic initiation factor 4G gene mediates greater than 100-fold higher expression of the downstream gene compared with the EMCV IRES in four different cell lines tested. Other mammalian IRESes displayed more variable results and smaller enhancement of downstream gene expression in three different cell lines tested. Furthermore, while the efficiency of the IRES from the vascular endothelium growth factor gene was not significantly higher than the EMCV IRES under normoxic conditions, expression was significantly increased under hypoglycemic conditions, suggesting that the VEGF IRES could be exploited in cancer gene therapy to preferentially target expression of therapeutic genes at the relatively hypoglycemic cores of tumors.
Subject(s)
Encephalomyocarditis virus/genetics , Endothelial Growth Factors/genetics , Genetic Therapy/methods , Genetic Vectors/genetics , Lymphokines/genetics , Neoplasms/therapy , Gene Expression , Humans , Hypoglycemia/metabolism , Ribosomes , Transfection , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
Diffusion weighted MRI was performed on patients with acute vertebral body compression. The usefulness of the apparent diffusion coefficient (ADC) in differentiating between benign and malignant fractures was evaluated. A total of 49 acute vertebral body compression fractures were found in 32 patients. 25 fractures in 18 patients were due to osteoporosis, 18 fractures in 12 patients were histologically proven to be due to malignancy, and 6 fractures in 2 patients were due to tuberculosis. Signal intensities on T(1) weighted, short tau inversion recovery (STIR) and diffusion weighted images were compared. ADC values of normal and abnormal vertebral bodies were calculated. Except for two patients with sclerotic metastases, benign acute vertebral fractures were hypointense and malignant acute vertebral fractures were hyperintense with respect to normal bone marrow on diffusion weighted images. Mean combined ADCs (ADC(cmb); average of the combined ADCs in the x, y and z diffusion directions) were 0.23 x 10(-3) mm(2) s(-1) in normal vertebrae, 0.82 x 10(-3) mm(2) s(-1) in malignant acute vertebral fractures and 1.94 x 10(-3) mm(2) s(-1) in benign acute vertebral fractures. The differences between ADC(cmb) values were statistically significant (p<0.001). The ADC is useful in differentiating benign from malignant acute vertebral body compression fractures, but there may be overlapping ADC values between malignant fractures and tuberculous spondylitis.
Subject(s)
Fractures, Spontaneous/etiology , Spinal Fractures/etiology , Spinal Neoplasms/diagnosis , Spinal Neoplasms/secondary , Acute Disease , Aged , Diagnosis, Differential , Female , Fractures, Spontaneous/diagnosis , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Osteoporosis/complications , Osteoporosis/diagnosis , Spinal Fractures/diagnosis , Tuberculosis, Spinal/complications , Tuberculosis, Spinal/diagnosisABSTRACT
CT is an advanced imaging modality, but the imaging parameters are normally selected subjectively. For standard head examinations, most of the parameters used are consistent amongst different centres, with the exception of large variations in the selection of the tube current-exposure time product (mAs). As a result, CT images may contain unacceptable levels of noise, or the patient may receive excessive radiation. In this study, the maximum anteroposterior diameter (MAPD) was shown to be a good criterion for mAs selection, and could be measured in a pilot view. 200 paediatric brain CT studies were randomly selected to determine the MAPD at the mid brain level. With knowledge of MAPD distribution, a phantom study was performed to determine the relationship between MAPD and the mAs required for consistent and acceptable image noise. It was found that the required mAs increased linearly with MAPD. Assuming the manufacturer's recommended value is "appropriate" for the average MAPD, the appropriate mAs value could be estimated. Using this method, appropriate mAs values were calculated retrospectively for a group of 240 randomly selected paediatric brain CT studies and compared with the actual mAs subjectively determined by the radiographer. Although their average values were similar, the difference between the calculated and actual values deviated markedly in some cases. When the actual mAs was smaller than the calculated value, higher image noise was observed. However, reduction of image noise was barely observed when the applied mAs was larger than the calculated value. Thus, this method is more objective and appropriate for determination of the mAs value for paediatric brain CT than the traditional subjective method.
Subject(s)
Brain Diseases/diagnostic imaging , Brain/diagnostic imaging , Clinical Protocols , Skull/pathology , Tomography, X-Ray Computed/methods , Brain Diseases/pathology , Child , Child, Preschool , Electronics , Humans , Infant , Phantoms, Imaging , Radiation Dosage , Tomography, X-Ray Computed/instrumentationABSTRACT
Although all mammalian COPII components have now been cloned, little is known of their interactions with other regulatory proteins involved in exit from the endoplasmic reticulum (ER). We report here that a mammalian protein (Yip1A) that is about 31% identical to S. cerevisiae and which interacts with and modulates COPII-mediated ER-Golgi transport. Yip1A transcripts are ubiquitously expressed. Transcripts of a related mammalian homologue, Yip1B, are found specifically in the heart. Indirect immunofluorescence microscopy revealed that Yip1A is localized to vesicular structures that are concentrated at the perinuclear region. The structures marked by Yip1A co-localized with Sec31A and Sec13, components of the COPII coat protein complex. Immunoelectron microscopy also showed that Yip1A co-localizes with Sec13 at ER exit sites. Overexpression of the hydrophilic N terminus of Yip1A arrests ER-Golgi transport of the vesicular stomatitis G protein and causes fragmentation and dispersion of the Golgi apparatus. A glutathione S-transferase fusion protein with the hydrophilic N terminus of Yip1A (GST-Yip1A) is able to bind to and deplete vital components from rat liver cytosol that is essential for in vitro vesicular stomatitis G transport. Peptide sequence analysis of cytosolic proteins that are specifically bound to GST-Yip1A revealed, among other proteins, mammalian COPII components Sec23 and Sec24. A highly conserved domain at the N terminus of Yip1A is required for Sec23/Sec24 interaction. Our results suggest that Yip1A is involved in the regulation of ER-Golgi traffic at the level of ER exit sites.
Subject(s)
Carrier Proteins/metabolism , Endoplasmic Reticulum/chemistry , Membrane Proteins/metabolism , Phosphoproteins/metabolism , Amino Acid Sequence , Animals , CHO Cells , COP-Coated Vesicles/metabolism , Carrier Proteins/genetics , Carrier Proteins/isolation & purification , Cell Compartmentation , Chlorocebus aethiops , Cricetinae , Golgi Apparatus , HeLa Cells , Humans , Membrane Proteins/genetics , Membrane Proteins/isolation & purification , Mice , Molecular Sequence Data , Phosphoproteins/genetics , Phosphoproteins/isolation & purification , Protein Binding , Protein Transport , Proteins/metabolism , Receptors, Peptide/isolation & purification , Saccharomyces cerevisiae Proteins , Sequence Homology, Amino Acid , Vero Cells , Vesicular Transport ProteinsSubject(s)
Lymphoma, B-Cell/pathology , Pinealoma/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease Progression , Fatal Outcome , Fatigue/etiology , Female , Humans , Low Back Pain/etiology , Lymphoma, B-Cell/drug therapy , Magnetic Resonance Imaging , Memory Disorders/etiology , Pinealoma/drug therapyABSTRACT
The yeast coat protein II (COPII) is responsible for vesicle budding from the endoplasmic reticulum (ER). Mammalian functional homologues for all yeast COPII components, except for Sec31p, have been reported. We have cloned a mammalian cDNA whose product (Sec31A) is about 26% identical to Saccharomyces cerevisiae Sec31p. Data base searches also revealed another partial sequence encoding a polypeptide (Sec31B) that is 40% identical to Sec31A. Northern analysis revealed that Sec31A transcripts are ubiquitously and abundantly expressed, while Sec31B transcripts are particularly enriched in the testis and thymus, but present in very low levels in other tissues. Sec31A is localized to vesicular structures that scatter throughout the cell but are concentrated at the perinuclear region. The structures marked by Sec31A contain Sec13, a component of COPII that is well characterized to mark the ER exit sites. Immunoelectron microscopy revealed that Sec31A colocalizes with Sec13 in structures with extensive vesicular-tubular profiles. Antibodies raised against a C-terminal portion of Sec31A co-precipitate Sec13 and inhibit ER-Golgi transport of temperature-arrested vesicular stomatitis G protein in a semi-intact cell assay. Cytosol immunodepleted of Sec31A failed to support vesicular stomatitis G protein transport, which can be rescued by a high molecular weight fraction of the cytosol containing both Sec31A and Sec13. We conclude that Sec31A represents a functional mammalian homologue of yeast Sec31p.
Subject(s)
Carrier Proteins/genetics , Genes, Fungal , Phosphoproteins/genetics , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae/genetics , Amino Acid Sequence , Animals , Biological Transport , Cloning, Molecular , DNA, Complementary/genetics , DNA, Complementary/isolation & purification , Endoplasmic Reticulum/metabolism , Golgi Apparatus/metabolism , Mammals , Molecular Sequence Data , Saccharomyces cerevisiae/ultrastructure , Sequence Homology, Amino Acid , Vesicular Transport ProteinsABSTRACT
PURPOSE: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. PATIENTS AND METHODS: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. RESULTS: Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31% for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. CONCLUSION: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Astrocytoma/drug therapy , Astrocytoma/pathology , Brain Neoplasms/drug therapy , Glioblastoma/drug therapy , Glioblastoma/pathology , Adolescent , Adult , Astrocytoma/classification , Brain Neoplasms/classification , Brain Neoplasms/pathology , Glioblastoma/classification , Humans , Karnofsky Performance Status , Logistic Models , Middle Aged , Neoplasm Recurrence, Local , Probability , Prognosis , Proportional Hazards Models , Salvage Therapy , Treatment OutcomeABSTRACT
Neutrophil elastase, proteinase-3, and azurocidin are primary components of neutrophil azurophilic granules and are encoded by closely linked genes (gene symbols ELA2, PRTN3, and AZU1, respectively) in a region of approximately 50 kb. These genes are coordinately expressed in a granulocyte-specific fashion, but the mechanisms defining this pattern of expression are unknown. To understand the role of chromatin organization in governing the expression of ELA2, PRTN3, and AZU1, we mapped this region of chromosome 19 and identified the adipsin (complement factor D) gene in proximity to the 3' end of ELA2. We then examined the changes in chromatin structure at the locus which accompany myeloid cell differentiation and identified 17 DNase I hypersensitive sites (DHS 1 to 17) in U-937 cells, an early myelomonocytic cell line expressing high levels of neutrophil elastase. Chemically induced differentiation and concomitant downregulation of AZU1, PRTN3, and ELA2 transcription in U-937 cells is not accompanied by changes in the DHS-pattern. Mature neutrophils, however, do not carry any of these hypersensitive sites, indicating a large degree of chromatin remodeling at this locus accompanying terminal granulocytic differentiation. Sixteen of the 17 DHS identified in U-937 cells are also present in the HL-60 myelomonocytic cell line. Hematopoietic cell lines representing the early erythroid and lymphocyte lineages, and a nonhematopoietic cell line display a subset of the hypersensitive sites. The altered chromatin structure specific to cells that actively transcribe the AZU1-PRTN3-ELA2 genes suggests that chromatin reorganization is an important mechanism regulating the myeloid-specific transcription of this gene cluster.
Subject(s)
Chromatin/genetics , Chromosomes, Human, Pair 19 , Leukocyte Elastase/genetics , Leukopoiesis/genetics , Chromatin/ultrastructure , Chromosome Mapping , Gene Expression Regulation , Genetic Linkage , HL-60 Cells , Humans , U937 CellsABSTRACT
In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.